Xarelto Monotherapy Noninferior To Combination Therapy For Cv | Latest News RSS feed

Xarelto Monotherapy Noninferior To Combination Therapy For Cv - Latest News

Xarelto monotherapy noninferior to combination therapy for CV

Xarelto monotherapy was noninferior to Xarelto plus an antiplatelet agent in regards to CV events and death from any cause in patients with atrial fibrillation and stable coronary artery disease, ... read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

AFIRE Encourages Less Antiplatelet Use With NOACs in Stable CAD With Atrial Fib

At the same time, the risk for major bleeding fell by about 40% among patients on NOAC monotherapy with rivaroxaban (Xarelto ... increase in all-cause mortality in the combination therapy group. read more

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

LAA occlusion was noninferior to NOAC therapy for composite clinical and bleeding events through a mean follow-up of 20.8 months, a result that was consistent in per-protocol and on-treatment analyses ... read more

Looking for another news?

NOAC Best Given Alone for Afib With Stable Heart Disease

PARIS -- Adding an antiplatelet to rivaroxaban (Xarelto ... 0.55 for monotherapy, 95% CI 0.38-0.81), which was significantly higher for both cardiovascular and noncardiovascular causes. While the ... read more

JNJ, Merck to Take the Stage at ESC

The study utilized a lower dose of Xarelto (5 milligrams (mg) twice a day as monotherapy or 2.5 mg twice a day in combination with aspirin ... With two different treatment arms, how each one performed ... read more

Cardiovascular Disease: Recent Drug Advances and Impending Risks

This new research report examines in detail the key areas of the cardiovascular (CV) market ... Summary of evacetrapid monotherapy data (change from baseline) at 24 weeks 94Table 59: Summary of ... read more

Bristol-Myers Squibb's (BMY) Management Presents At Morgan Stanley Healthcare Conference (Transcript)

Our last NBRx share in cardiology was above 40% and is at about 5 points delta to Xarelto at ... across lines of therapy, but ultimately because we feel that in the frontline setting, the value that ... read more

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis

Bolen. Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. Purpose: To evaluate the comparative ... read more

Expectations High for Insulin GLP-1 Combinations in Diabetes Care

ā€œIā€™m not yet sure that the combination is always superior to a GLP ... Subsequent analysis found IDegLira noninferior to insulin degludec (estimated treatment difference, ā€“0.47%; 95% confidence ... read more

ATMOSPHERE: Aliskiren With or Without Enalapril Not Superior to Enalapril Alone in HF

or even significantly noninferior (in the monotherapy group) to enalapril by itself in rates of CV death or HF-related hospitalization (the primary composite outcome). "Our combination-therapy results ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us